low-grade serous carcinoma · human disease · YYNN

low-grade serous carcinoma

? TBD

human disease

Ratings
0

Nobody has rated this yet. Be the first!

Researchers
2

Brian Slomovitz

gynecologic oncologist, researcher

Gynecologic oncology surgeon, professor, researcher

Instances
1

Influences rating

Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer

Subject of
5

PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

scientific article published in June 2022

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

Low-grade serous ovarian cancer: expert consensus report on the state of the science

scientific article published on 17 August 2023

Lists
0

Subclass of

Serous carcinoma

Facet of

Wikidata